Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Monday, January 13, 2020 at 10:00 a.m. PST / 6:00 p.m. GMT.
A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
An archive of the webcast will be available on the website for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Sunosi® (solriamfetol), Xyrem® (sodium oxybate) oral solution, Defitelio® (defibrotide sodium), Erwinaze® (asparaginase Erwinia chrysanthemi) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio® (defibrotide), Erwinase® and Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. For country-specific product information, please visit www.jazzpharmaceuticals.com/medicines. For more information, please visit www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.
Jazz Pharmaceuticals Contacts: |
|
Investors: |
Media: |
Kathee Littrell |
Jacqueline Kirby |
Vice President, Investor Relations |
Vice President, Corporate Affairs & Government Relations |
Ireland, +353 1 634 7887 |
Ireland, +353 1 697 2141 |
U.S., +1 650 496 2717 |
U.S., +1 215 867 4910 |
Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg
Share this article